Mar 07, 2011 16:00 JST

Source: China Medical System Holdings Limited

China Medical System Accredited by 'China's Top 100 Potential Enterprises' by Forbes China for Two Consecutive Years

HONG KONG, Mar 07, 2011 - (ACN Newswire) - China Medical System Holdings Limited ("CMS" or the "Company", SEHK: 867), a leading China-based pharmaceutical services company focusing on the marketing, promotion and sale of prescription drugs, is pleased to announce that the Company was accredited as "China's Top 100 Potential Enterprises" among the list compiled by the Forbes China in February 2011. CMS has been selected on the list for two consecutive years.

Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries. This is the second consecutive year that CMS has won the coveted accolade for its outstanding business performance and contribution to the development of China's SMEs, and for its efforts to strive for excellence in its field.

About "China's Top 100 Potential Enterprises" by Forbes China
http://www.forbeschina.com/list/1008/more

Contact:
Hill and Knowlton Asia Ltd.

Crystal Yip  
Tel: +852 2894 6211 / 9720 6445
Email: crystal.yip@hillandknowlton.com.hk

James Wong
Tel: +852 2894 6216 / 9300 2263
Email: james.wong@hillandknowlton.com.hk
Source: China Medical System Holdings Limited
Sectors: BioTech

Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Related Press Release


CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
October 30 2025 20:00 JST
 
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
October 27 2025 22:00 JST
 
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
September 28 2025 15:00 JST
 
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
September 23 2025 12:15 JST
 
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
August 19 2025 15:00 JST
 
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
July 29 2025 04:00 JST
 
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets
July 22 2025 13:00 JST
 
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
April 01 2024 20:30 JST
 
CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013
January 28 2011 12:00 JST
 
China Medical System Holdings Issues FY2010 Earnings Guidance
January 12 2011 11:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>